Physician profile
Adan Gonzalez
NPI 1528249745
$4,700.18
in general payments reported to CMS, 2019-2025
28 companies · $806 in 2025
The $806 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $326 · 2021: $372 · 2022: $465 · 2023: $890 · 2024: $1,147 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,768 · Education: $75.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,767.71 |
| Education | $75.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $744.61 | 2019-2025 | Jynarque, Voyxact |
| Novartis Pharmaceuticals Corporation | $612.87 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $515.46 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $306.15 | 2019-2025 | Farxiga |
| Fresenius USA Marketing, INC. | $254.68 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Aurinia Pharma U.S., INC. | $219.05 | 2021-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $192.30 | 2019-2022 | |
| Amgen INC. | $182.83 | 2023-2025 | Tavneos, Krystexxa |
| Travere Therapeutics, INC. | $179.68 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.24 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $167.40 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $151.24 | 2019-2024 | Veltassa |
| Ardelyx, INC. | $143.11 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $123.03 | 2024-2025 | Ozempic, Wegovy, Rivfloza |
| Baxter Healthcare | $122.34 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $97.46 | 2020-2024 | Injectafer |
| Outset Medical INC | $80.02 | 2024 | |
| Mallinckrodt Hospital Products INC. | $78.78 | 2020-2025 | Terlivaz |
| Opko Pharmaceuticals, LLC | $61.12 | 2019-2020 | |
| Glaxosmithkline, LLC. | $54.95 | 2021-2025 | Benlysta |
| Horizon Therapeutics Plc | $47.29 | 2020-2021 | |
| Akebia Therapeutics INC | $46.97 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $31.67 | 2020-2023 | |
| W. L. Gore & Associates, INC. | $26.75 | 2024 | Gore Acuseal Vascular Graft |
| Pharmacosmos Therapeutics INC. | $25.45 | 2024 | Monoferric |
| Amicus Therapeutics, INC. | $23.38 | 2022 | |
| Genentech USA, INC. | $18.73 | 2019 | |
| Genzyme Corporation | $17.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adan Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.